Halozyme Therapeutics
(NASDAQ:HALO)
$40.37
-0.49[-1.20%]
At close: Mar 18
$40.37
0[0.00%]
After Hours: 4:00PM EDT

GET A REPORT ON HALO SENT RIGHT TO YOUR INBOX

Halozyme Therapeutics Stock (NASDAQ:HALO), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.
Consensus Rating1
Overweight
Highest Price Target1
$72.00
Lowest Price Target1
$40.00
Consensus Price Target1
$48.47

Analyst Rating Summary1

Analyst Ratings
Oct 23
3
Dec 23
1
Jan
3
1
Feb
2
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

TD Cowen
JMP Securities
HC Wainwright & Co.
Benchmark
Goldman Sachs

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Halozyme Therapeutics

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
02/29/2024HALOBuy Now
Halozyme Therapeutics
$40.3733.76%TD Cowen
Brendan Smith
→ $54Initiates → OutperformGet Alert
02/21/2024HALOBuy Now
Halozyme Therapeutics
$40.3778.35%JMP Securities
Jason Butler
→ $72ReiteratesMarket Outperform → Market OutperformGet Alert
02/21/2024HALOBuy Now
Halozyme Therapeutics
$40.3723.85%HC Wainwright & Co.
Mitchell Kapoor
$48 → $50MaintainsBuyGet Alert
01/19/2024HALOBuy Now
Halozyme Therapeutics
$40.3723.85%Benchmark
Robert Wasserman
→ $50ReiteratesBuy → BuyGet Alert
01/19/2024HALOBuy Now
Halozyme Therapeutics
$40.3718.9%HC Wainwright & Co.
Mitchell Kapoor
→ $48ReiteratesBuy → BuyGet Alert
01/18/2024HALOBuy Now
Halozyme Therapeutics
$40.3778.35%JMP Securities
Jason Butler
→ $72ReiteratesMarket Outperform → Market OutperformGet Alert
01/18/2024HALOBuy Now
Halozyme Therapeutics
$40.37-0.92%Goldman Sachs
Graig Suvannavejh
$45 → $40MaintainsNeutralGet Alert
01/18/2024HALOBuy Now
Halozyme Therapeutics
$40.3718.9%HC Wainwright & Co.
Mitchell Kapoor
$61 → $48MaintainsBuyGet Alert
12/26/2023HALOBuy Now
Halozyme Therapeutics
$40.3746.15%Morgan Stanley
Vikram Purohit
$61 → $59MaintainsOverweightGet Alert
10/20/2023HALOBuy Now
Halozyme Therapeutics
$40.3723.85%Benchmark
Robert Wasserman
→ $50ReiteratesBuy → BuyGet Alert
10/19/2023HALOBuy Now
Halozyme Therapeutics
$40.3751.1%HC Wainwright & Co.
Mitchell Kapoor
$60 → $61MaintainsBuyGet Alert
10/09/2023HALOBuy Now
Halozyme Therapeutics
$40.3748.63%HC Wainwright & Co.
Mitchell Kapoor
→ $60ReiteratesBuy → BuyGet Alert
09/08/2023HALOBuy Now
Halozyme Therapeutics
$40.3748.63%HC Wainwright & Co.
Mitchell Kapoor
→ $60ReiteratesBuy → BuyGet Alert
08/30/2023HALOBuy Now
Halozyme Therapeutics
$40.3748.63%HC Wainwright & Co.
Mitchell Kapoor
→ $60ReiteratesBuy → BuyGet Alert
08/15/2023HALOBuy Now
Halozyme Therapeutics
$40.3748.63%HC Wainwright & Co.
Mitchell Kapoor
$61 → $60MaintainsBuyGet Alert
08/10/2023HALOBuy Now
Halozyme Therapeutics
$40.3751.1%Morgan Stanley
Vikram Purohit
$60 → $61MaintainsOverweightGet Alert
07/24/2023HALOBuy Now
Halozyme Therapeutics
$40.3751.1%HC Wainwright & Co.
Mitchell Kapoor
→ $61Initiates → BuyGet Alert
07/24/2023HALOBuy Now
Halozyme Therapeutics
$40.3711.47%Goldman Sachs
Graig Suvannavejh
$43 → $45DowngradeBuy → NeutralGet Alert
05/10/2023HALOBuy Now
Halozyme Therapeutics
$40.3763.49%JMP Securities
Jason Butler
→ $66Reiterates → Market OutperformGet Alert

FAQ

Q

What is the target price for Halozyme Therapeutics (HALO)?

A

The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by TD Cowen on February 29, 2024. The analyst firm set a price target for $54.00 expecting HALO to rise to within 12 months (a possible 33.76% upside). 22 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Halozyme Therapeutics (HALO)?

A

The latest analyst rating for Halozyme Therapeutics (NASDAQ: HALO) was provided by TD Cowen, and Halozyme Therapeutics initiated their outperform rating.

Q

When is the next analyst rating going to be posted or updated for Halozyme Therapeutics (HALO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Halozyme Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Halozyme Therapeutics was filed on February 29, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.

Q

Is the Analyst Rating Halozyme Therapeutics (HALO) correct?

A

While ratings are subjective and will change, the latest Halozyme Therapeutics (HALO) rating was a initiated with a price target of $0.00 to $54.00. The current price Halozyme Therapeutics (HALO) is trading at is $40.37, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch